Breast Cancer Clinical Trial
Official title:
The Risk of Postoperative Wound Complications Following the Use of Avelle Negative Pressure Wound Therapy in Patients Undergoing Mastectomy and Flap fiXation: a Pilot Study
To evaluate the risk of postoperative wound complications following the use of Avelle negative pressure wound therapy in patients undergoing mastectomy and flap fixation, which might serve as a basis for a randomized controlled trial
Rationale:
Patients and breast cancer surgeons are frequently confronted with complications after
mastectomy. These complications are manifold and mainly consist of: surgical site infections,
seroma, wound dehiscence and wound necrosis. These complications are caused by numerous
variables and therefore a multifactorial approach is required. Due to extensive research over
the years, insight has been gained in how to reduce the rate of surgical site infections and
wound healing problems. For example, pre-operatively and intra-operatively the complication
rate can partly be influenced by optimizing intrinsic patient factors before surgery and
using prophylactic antibiotics (1). There is however room for improvement in the
postoperative phase. Negative pressure wound therapy (NPWT) has proven to be useful in
reducing wound complications in all sorts of wounds. Limited evidence has been published on
NPWT after breast cancer surgery and the effect of such in reducing wound complications.
This is a pilot study to evaluate the effect of negative pressure wound therapy in reducing
postoperative wound complications after mastectomy, which might serve as a basis for a
randomized controlled trial..
Objective:
To evaluate the risk of postoperative wound complications following the use of Avelle
negative pressure wound therapy in patients undergoing mastectomy and flap fixation, which
might serve as a basis for a randomized controlled trial
Study design:
A prospective cohort will be compared to a historical control group. Fifty consecutive
patients will undergo mastectomy with flap fixation using tissue glue and skin sutures,
closed suction drainage AND Avelle negative pressure wound therapy.
These results will be compared to the results of a historical control group consisting of 112
patients who have undergone mastectomy with flap fixation using tissue glue and sutures and
closed suction drainage and in whom negative wound pressure therapy was omitted.
Follow-up will be conducted for three months post mastectomy.
Study population:
Female patients > 18 years diagnosed with invasive breast cancer or DCIS ( ductal carcinoma
in situ) with an indication to perform mastectomy.
Intervention (if applicable):
Application of Avelle negative pressure wound therapy after standard mastectomy with flap
fixation and closed suction drainage.
Main study parameters/endpoints:
Patients with postoperative wound complications during the first three postoperative months.
Nature and extent of the burden and risks associated with participation, benefit and group
relatedness:
Patients will be informed about the study before inclusion in the outpatient clinic. Informed
consent will be obtained in the outpatient clinic a week after patients were initially
informed. Postoperative check-ups will be done more frequently. Standard postoperative
check-ups are planned at one week and three months. Additional study postoperative check-up
will be performed at six weeks. Therefore, patients will be required to undergo one
additional check-up. During out patients' visits, wound complication will be evaluated.
Application of Avelle negative pressure wound therapy is expected to reduce wound
complications and thereby benefit the post mastectomy wound healing process. The only
potential risk for the patient is that the wound therapy would be ineffective or that the
patient could develop an allergic reaction to the product. The latter is also a known risk of
standard wound dressings.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A |